205 related articles for article (PubMed ID: 6259357)
1. Cytomegalovirus-specific immune response and the cellular immune status of malignant lymphoma.
ten Napel CH; van Egten-Bijker J; Halie MR; Langenhuysen MM; The TH
J Clin Lab Immunol; 1980 Nov; 4(3):145-51. PubMed ID: 6259357
[TBL] [Abstract][Full Text] [Related]
2. Immunological characterization of Hodgkin's and non-Hodgkin's lymphoma patients with high antibody titers against Epstein-Barr virus-associated antigens.
Masucci G; Mellstedt H; Masucci MG; Szigeti R; Ernberg I; Björkholm M; Tsukuda K; Henle G; Henle W; Pearson G
Cancer Res; 1984 Mar; 44(3):1288-300. PubMed ID: 6318984
[TBL] [Abstract][Full Text] [Related]
3. Antibodies against herpesviruses in patients with Hodgkin's disease.
Wutzler P; Färber I; Sprössig M; Sauerbrei A; Wutke K; Höche D; Rüdiger KD; Wöckel W; Scheibner K
Arch Geschwulstforsch; 1983; 53(5):417-22. PubMed ID: 6316868
[TBL] [Abstract][Full Text] [Related]
4. Discordance of Epstein-Barr Virus (EBV) specific humoral and cellular immunity in patients with malignant lymphomas: elevated antibody titres and lowered in vitro lymphocyte reactivity.
Ten Napel CH; The TH; Van Egten-Bijker J; de Gast GC; Halie MR; Langenhuysen MM
Clin Exp Immunol; 1978 Dec; 34(3):338-46. PubMed ID: 217561
[TBL] [Abstract][Full Text] [Related]
5. Identification and characterization of an Epstein-Barr virus-specific T-cell response in the pathologic tissue of a patient with Hodgkin's disease.
Dolcetti R; Frisan T; Sjöberg J; De Campos-Lima PO; Pisa P; De Re V; Gloghini A; Rizzo S; Masucci MG; Boiocchi M
Cancer Res; 1995 Aug; 55(16):3675-81. PubMed ID: 7627978
[TBL] [Abstract][Full Text] [Related]
6. Maintenance of cytomegalovirus (CMV) latency and host immune responses of long term renal allograft survivors. II. Secondary CMV infections associated with impaired in vitro proliferative responses to mitogens, allogeneic lymphocytes and CMV infected cells.
Roenhorst HW; Beelen JM; Middeldorp JM; Schirm J; Tegzess AM; The TH
Clin Exp Immunol; 1985 Jul; 61(1):72-9. PubMed ID: 2994923
[TBL] [Abstract][Full Text] [Related]
7. [Elevated Epstein-Barr virus antibodies in patients with Hodgkin's disease].
Kuljić-Kapulica N
Srp Arh Celok Lek; 1998; 126(3-4):97-100. PubMed ID: 9863363
[TBL] [Abstract][Full Text] [Related]
8. Correlation between mixed lymphocyte cultures and anti-Epstein Barr virus (EBV) antibodies in Hodgkin's disease and non Hodgkin lymphoma patients.
Sasiain MC; Fejes M; Ares BR; Brezavscek D; Bachmann AE
Biomedicine; 1981 Oct; 35(5):153-6. PubMed ID: 6274439
[TBL] [Abstract][Full Text] [Related]
9. Altered humoral immunity against cytomegalovirus and Epstein-Barr virus without detectable virus antigens and virus-DNA in the glomeruli of patients with IGA nephropathy in remission phase.
Nagy J; Haikin H; Sarov B; Háber A; Kun L; Sarov I
Acta Microbiol Immunol Hung; 1995; 42(2):179-87. PubMed ID: 7551711
[TBL] [Abstract][Full Text] [Related]
10. [Comparative study of anti EBV antibodies in non-Hodgkin's lymphomams and angio-immunoblastic lymphadenopathies (author's transl)].
Dumont J; Liabeuf A; Henle W; Ferchal F; Feingold N; Kourilsky FM
Bull Cancer; 1979; 66(4):373-81. PubMed ID: 230873
[TBL] [Abstract][Full Text] [Related]
11. The cellular immune response to cell-associated and cell-free cytomegalovirus (CMV) antigens after primary CMV-infection in non-immunocompromised hosts: development and maintenance of CMV-latency and its influence on immunocompetence.
Roenhorst HW; Kallenberg CG; The TH
Clin Exp Immunol; 1988 Dec; 74(3):326-32. PubMed ID: 2853014
[TBL] [Abstract][Full Text] [Related]
12. Invited discussion: relationship of titers of Epstein-Barr virus to cell-mediated immunity in patients with Hodgkin's disease.
Levine PH; Reisher JI
Natl Cancer Inst Monogr; 1973 May; 36():85-7. PubMed ID: 4355354
[No Abstract] [Full Text] [Related]
13. Deficiency of cytomegalovirus (CMV)-specific CD8+ T cells in patients presenting with late-onset CMV disease several years after transplantation.
Cummins NW; Deziel PJ; Abraham RS; Razonable RR
Transpl Infect Dis; 2009 Feb; 11(1):20-7. PubMed ID: 18811629
[TBL] [Abstract][Full Text] [Related]
14. Epstein-barr virus-associated non-Hodgkin's lymphoma of B-cell origin, Hodgkin's disease, acute leukemia, and systemic lupus erythematosus: a serologic and molecular analysis.
Mitarnun W; Pradutkanchana J; Takao S; Saechan V; Suwiwat S; Ishida T
J Med Assoc Thai; 2002 May; 85(5):552-9. PubMed ID: 12188384
[TBL] [Abstract][Full Text] [Related]
15. Impaired lymphocyte transformation in Hodgkin's disease. Evidence for depletion of circulating t-lymphocytes.
Matchett KM; Huang AT; Kremer WB
J Clin Invest; 1973 Aug; 52(8):1908-17. PubMed ID: 4541673
[TBL] [Abstract][Full Text] [Related]
16. Cell-mediated immune reactions in three patients with malignant lymphoproliferative diseases in remission and abnormally high Epstein-Barr virus antibody titers.
Masucci MG; Szigeti R; Ernberg I; Björkholm M; Mellstedt H; Henle G; Henle W; Pearson G; Masucci G; Svedmyr E; Johansson B; Klein G
Cancer Res; 1981 Nov; 41(11 Pt 1):4292-301. PubMed ID: 6272973
[TBL] [Abstract][Full Text] [Related]
17. Clinical and virological observations in childhood Hodgkin's disease in Israel.
Bogger-Goren S; Zaizov R; Vogel R; Leventon-Kriss S; Sayar Y; Gotlieb-Stematsky T
Isr J Med Sci; 1983 Nov; 19(11):989-91. PubMed ID: 6319327
[TBL] [Abstract][Full Text] [Related]
18. High levels of CMV-IE-1-specific memory T cells are associated with less alloimmunity and improved renal allograft function.
Nickel P; Bold G; Presber F; Biti D; Babel N; Kreutzer S; Pratschke J; Schönemann C; Kern F; Volk HD; Reinke P
Transpl Immunol; 2009 Mar; 20(4):238-42. PubMed ID: 19032982
[TBL] [Abstract][Full Text] [Related]
19. Cytomegalovirus-directed lymphocyte reactivity in healthy adults tested by a CMV-induced lymphocyte transformation test.
Ten Napel CH; The TH; Bijker J; De Gast GC; Langenhuysen MM
Clin Exp Immunol; 1977 Jul; 29(1):52-60. PubMed ID: 70294
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy.
Chapman AL; Rickinson AB; Thomas WA; Jarrett RF; Crocker J; Lee SP
Cancer Res; 2001 Aug; 61(16):6219-26. PubMed ID: 11507075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
